Clinical Utility of Droplet Digital PCR on Liquid Biopsies from Patients with Castration-Resistant Prostate Cancer
Available on demand
The Treatment Resistance Team at the Institute of Cancer Research has been using plasma to interrogate resistance in castration-resistant prostate cancer (CRPC) and develop biomarkers for selecting treatment. Using targeted next-generation sequencing and droplet digital PCR on cfDNA from sequential plasma samples, AR mutations were found to emerge with resistance to abiraterone. A strong association between plasma AR aberrations and resistance to abiraterone in heavily-pre-treated CRPC patients was also seen, supporting the clinical utility of cfDNA studies in metastatic prostate cancer.
In this webinar, Daniel Wetterskog, PhD, Senior Scientific Officer, Institute of Cancer Research, UK, will discuss:
- Liquid biopsy studies in castration-resistant prostate cancer
- Droplet digital PCR (ddPCR) technology and methodologies
- Utilizing ddPCR in the management of castration-resistant prostate cancer
Bio-Rad